NCT07717710RecruitingEarly phase 1
Ivabradine for Heart Rate Reduction During Exercise in Healthy Adults
Heart Rate Reduction Via Oral Ivabradine During Exercise in Healthy Adults to Understand Heart Rate/Work-rate Relations: A Pilot Dose-selection Study
Source: ClinicalTrials.gov · Last updated 9 Oct 2026
Brief summary (registry, in English)
During exercise, working muscles require more oxygen. The heart meets this demand in two ways: by beating faster (heart rate) and by pumping more blood with each beat (stroke volume). Heart rate increases steadily with exercise intensity until exhaustion, but the amount of blood pumped with each beat tends to plateau at moderate intensities. Why the amount of blood pumped with each beat becomes limited before heart rate, however, is not well understood. Studying these mechanisms is difficult because most drugs that lower heart rate also affect how strongly the heart pumps, making it hard to separate the two effects. One medication that can help with this is ivabradine, which is used to treat people with heart disease who have high resting heart rates. It slows the heart rate without changing how strongly the heart pumps. This study will investigate whether ivabradine lowers heart rate during exercise in healthy younger and older adults, and whether a higher dose lowers heart rate more. The results will help us better understand how heart rate influences the heart's ability to supply oxygen to the body during exercise, and what limits the ability to exercise as people age. Participants will: * Attend three visits at SportsCardiologyBC in Vancouver * Complete a cycling exercise test at each visit to measure heart rate and how hard they can exercise * Take ivabradine (a heart-rate-lowering medication) before the exercise test at Visits 2 and 3 (a lower dose at Visit 2 and a higher dose at Visit 3) * Be monitored for side effects including slow heart rate, visual symptoms, and headache.
- Status (registry)
- Recruiting
- Phase (registry)
- Early phase 1
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- First submitted
- 10 Jul 2026
- Start date
- 1 Oct 2026
- Primary completion date
- Dec 2026
- Lead sponsor
- University of British Columbia
- Diseases
- Stroke
- NCT number
- NCT07717710
What you commit to
- Study type: Interventional · Early phase 1
- Planned participants: 20
- From 1 Oct 2026 to the primary completion date, Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Use of any chronic medication
- Use of strong cytochrome P450 (CYP3A4) inhibitors (e.g., nirmatrelvir and ritonavir, ketoconazole), which can increase ivabradine levels in the blood to potentially unsafe levels
Other illness
- History of any cardiovascular condition, including hypertension
- History of any respiratory condition, including asthma
- History of diabetes mellitus, cancer, hepatic, renal or any other chronic illness
- Any condition that prevents vigorous exercise from being performed safely
- Seated resting heart rate \<60 beats per minute
- Sick sinus syndrome, sino-atrial block or third-degree atrio-ventricular block
- Use of verapamil or diltiazem, which are moderate CYP3A4 inhibitors and also lower heart rate, posing a risk of excessive bradycardia when combined with ivabradine
- Known allergy/hypersensitivity to ivabradine or to any ingredient in the formulation or component of the container
Lab values
- Prolonged QT interval (e.g., long QT syndrome)
Other
- Smoking, including cannabis or vaping in the past year
- Seated blood pressure ≥130/90 or \<100/60 mmHg
- Body mass index \<20 or \>32 kg/m2
- Non-sinus rhythm or abnormalities on 12-lead electrocardiogram (ECG)
- Pregnant, breastfeeding, or women of childbearing potential not using appropriate contraception
- Current or recent (past year) participation in \>150 minutes per week of moderate-vigorous intensity exercise (to avoid endurance training-related bradycardia)
- Lactose intolerance, as ivabradine contains lactose
Who the study is looking for
- Healthy males and females aged 19-39 years, and 60-79 years
- Engaging in regular aerobic exercise (e.g., running, cycling, swimming, hiking, field, ice, or racquet sports) at least once per week
Age in the registry: 19 years to 79 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| SportsCardiologyBC, UBC Hospital Coordinator of this site? Confirm its status | Vancouver | Canada | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.